Key result
Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy, emerging as a cardioprotective target in zebrafish.
Why the study?
Doxorubicin induces heart failure as a side effect, and therapeutic targets for clinical cardioprotection are needed.
Answers are grounded in this paper and cite their sources.
No immediate change to doxorubicin cardioprotection; leaves open Cyp1 inhibition as a target pending mammalian and human validation.
Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy in a zebrafish heart-failure model. Doxorubicin, a potent chemotherapy drug, has a side effect of inducing heart failure. By using a zebrafish doxorubicin-induced cardiomyopathy model for in vivo small-molecule screening, the cytochrome P450 family (CYP1) was identified as a candidate therapeutic target for clinical cardioprotection. More information can be found in the full paper by R. T. Peterson et al.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2020) studied Doxorubicin-induced cardiomyopathy. Cyp1 inhibition was evaluated on Prevention of doxorubicin-induced cardiomyopathy. Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy and was identified as a candidate therapeutic target for cardioprotection in a zebrafish heart-failure model.
Synapse has enriched 10 related papers. Consider them for comparative context: